Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: A phase II study

Acta Neurochirurgica

Volumn 138, Issue 2, 1996, Pages 215-220

  Lunardi, P ^a   Osman Farah, J ^a,b   Mastronardi, L ^a   Puzzilli, F ^a   Lo Bianco, F M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Neurochirurgia II Catt   (Italy)

Author keywords

Carboplatin; Cerebral gliomas; Chemotherapy; Nitrosurea

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030067640     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01411364     Document Type: Article

References (26)

1. Aida T, Bodell WJ (1987) Cellular resistance to chlorethylnitrosoureas, nitrogen mustard and cis-diamminedichloroplatinum II) in human glial-derived cell lines. Cancer Res 47: 1361-1366
2. Brufman G, Halpern J, Sukes R, Catane R, Biran S (1984) Procarbazine, CCNU, and vincristine combination chemotherapy for brain tumours. Oncology 41: 239-241
3. Cianfriglia F, Pompili A, Riccio A, Grassi A (1980) CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer 45: 1289-1299
4. Doy F, Berens ME, Dougherty DV, Rosenblum ML (1991) Comparison of the cytotoxic activities of cisplatin and carboplatin against gliomas cell lines at pharmalogically relevant drug exposure. J Neurooncol 11: 27-35
5. EORTC Brain Tumor Group (1978) Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma-final evaluation. Eur J Cancer 14: 851-856
6. EORTC Brain Tumor Group (1985) Evaluation of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6-dioxodiethylester) in recurring supratentorial malignant brain gliomas - a phase II study. Eur J Cancer Clin Oncol 21: 143-146
7. EORTC Brain Tumor Group (1981) Evaluation of CCNU, VM26, plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg 55: 27-31
8. Hochberg FD, Pruitt AA, Beck DO, DeBrun G, Davis K (1985) The rationale and the methodology for intra-arterial chemotherapy with BCNU as a treatment for glioblastoma. J Neurosurg 63: 876-880
9. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
10. Kornblith P, Walker M (1988) Chemotherapy for malignant gliomas. J Neurosurg 68: 1-17
11. Kumar ARV, Renaudin J, Wilson CB, Bodrey EB, Enot KJ, Levin VA (1974) Procarbazine hydrochloridein the treatment of brain tumors. A phase II study. J Neurosurg 40: 365-371
12. Levin A, Wilson CB, Davis R (1979) A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51: 526-532
13. Mahaley MS, Hipp SW, Dropcho EJ, Bertsch L, Cush S, Tirey T, Gillespie GY (1989) Intracarotid cisplatin chemotherapy for recurrent glioma. J Neurosurg 70: 371-378
14. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
15. Muggia FM (1989) Overview of carboplatin. Replasing, complementing and extending the therapeutic horizons of cisplatin. Semin Oncol 16 [Suppl 5]: 7-13
16. Papavero L, Loew F, Jakche H (1987) Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Acta Neurochir (Wien) 85: 128-137
17. Poisson M, Pereon Y, Chiras J, Delattre JY (1991) Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10: 139-144
18. Spence AM, Berger MS, Livingston RB (1992) Phase II evaluation of high dose intravenous cisplatin for the treatment of adult malignant gliomas recurrent after chloroethylnitrosurea failure. J Neurooncol 12: 187-191
19. Stewart DJ, O'Bryan RM, Al-Sarraf M (1983) Phase II study of cisplatin in recurrent astrocytomas in adults. A Southwest Oncology Group Study. J Neurooncol 1: 145-147
20. Twelves CJ, Ash CM, Miles DW, Thomas DG, Souhami RL (1991) Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 27: 481-483
21. Wagstaff A, Ward A, Benfield P, Heel RC (1989) Carboplatin, A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37: 162-190
22. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Hunt WE, MacCarty CS, Mahaley SM JR, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329
23. Walker WK, Mechtler L, Gleason MJ (1987) Intravenous carboplatin for recurrent glioma with carboplatin (CBDCA). Proc Am Soc Clin Oncol 6: 72
24. Warnick RE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19: 69-74
25. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48, Geneva
26. Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma. A phase II study. J Clin Oncol 9: 860-864